Pfizer has announced the selection of a preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, based on results from an ongoing pharmacokinetic study, reports Kazinform. A Kazinform correspondent contacted Pfizer, and the company emphasised it is too early to speculate on regulatory approvals and availability. It is also unclear which countries will be included in the initial distribution of this weight-loss pill, and whether Kazakhstan will be among them. Please, subscribe to Kazinfom News! Instagram: https://www.instagram.com/qazinform_agency/ Twitter: https://x.com/kazinform_eng Web: https://en.inform.kz/

Related Videos :







Pfizer advances weight-loss pill. What are the side effects? #news [vNwmq0fWx]

Pfizer advances weight-loss pill. What are the side effects? #news [vNwmq0fWx]

Pfizer has announced the selection of a preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, based on results from an ongoing pharmacokinetic study, reports Kazinform. A Kazinform correspondent contacted Pfizer, and the company emphasised it is too early to speculate on regulatory approvals and availability. It is also unclear which countries will be included in the initial distribution of this weight-loss pill, and whether Kazakhstan will be among them. Please, subscribe to Kazinfom News! Instagram: https://www.instagram.com/qazinform_agency/ Twitter: https://x.com/kazinform_eng Web: https://en.inform.kz/

Related Videos :

Aired: December 3rd 2024

Rating: TV-14

Buy Now:

Problems Playing Video? | Closed Captioning

Learn About Midwifery Today

Blog

Learn About Midwifery Today

Read the Modern Day Midwives Blog and learn more about our bloggers, all experienced midwives.

Read now